Dashboard
Manage Tickers

JNJ JOHNSON & JOHNSON

NYSE jnj.com


$ 198.93 $ 2.00 (1.02 %)    

Monday, 17-Nov-2025 11:10:09 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 606.86 $ 0.73 (0.12 %)
DIA $ 470.12 $ -0.71 (-0.15 %)
SPY $ 669.49 $ -0.24 (-0.04 %)
TLT $ 89.20 $ 0.12 (0.13 %)
GLD $ 373.29 $ -0.71 (-0.19 %)
$ 195.93
$ 196.53
$ 198.87 x 10
$ 198.92 x 6
$ 195.97 - $ 199.62
$ 137.37 - $ 197.18
8,824,847
na
472.05B
$ 0.30
$ 18.79
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 10-22-2025 09-28-2025 10-Q
2 07-24-2025 06-29-2025 10-Q
3 04-23-2025 03-30-2025 10-Q
4 02-13-2025 12-29-2024 10-K
5 10-23-2024 09-29-2024 10-Q
6 07-25-2024 06-30-2024 10-Q
7 05-01-2024 03-31-2024 10-Q
8 02-16-2024 12-31-2023 10-K
9 10-27-2023 10-01-2023 10-Q
10 10-27-2023 10-01-2023 10-Q
11 07-31-2023 07-02-2023 10-Q
12 04-28-2023 04-02-2023 10-Q
13 02-16-2023 01-01-2023 10-K
14 10-27-2022 10-02-2022 10-Q
15 07-29-2022 07-03-2022 10-Q
16 04-29-2022 04-03-2022 10-Q
17 02-17-2022 01-02-2022 10-K
18 10-29-2021 10-03-2021 10-Q
19 07-29-2021 07-04-2021 10-Q
20 04-30-2021 04-04-2021 10-Q
21 02-22-2021 01-03-2021 10-K
22 10-23-2020 09-27-2020 10-Q
23 07-24-2020 06-28-2020 10-Q
24 04-29-2020 03-29-2020 10-Q
25 02-18-2020 12-29-2019 10-K
26 10-28-2019 09-29-2019 10-Q
27 07-29-2019 06-30-2019 10-Q
28 05-01-2019 03-31-2019 10-Q
29 02-20-2019 12-30-2018 10-K
30 10-31-2018 09-30-2018 10-Q
31 08-02-2018 07-01-2018 10-Q
32 05-01-2018 04-01-2018 10-Q
33 02-21-2018 12-31-2017 10-K
34 11-02-2017 10-01-2017 10-Q
35 08-03-2017 07-02-2017 10-Q
36 05-08-2017 04-02-2017 10-Q
37 02-27-2017 01-01-2017 10-K
38 11-04-2016 10-02-2016 10-Q
39 08-04-2016 07-03-2016 10-Q
40 05-10-2016 04-03-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-reports-tremfya-delivers-sustained-joint-protection-and-significant-symptom-improvement-through-48-weeks-in-phase-3b-psoriatic-arthritis-study
Johnson & Johnson Reports TREMFYA Delivers...
11/17/2025 13:13:56

First-line treatment with TREMFYA® shows significant inhibition of radiographic progression at Week 24, which was sustained thr...

johnson--johnson-to-acquire-halda-therapeutics-opco-for-305b-in-cash-expects-2026-adj-eps-dilution-of-015share
Johnson & Johnson To Acquire Halda Therape...
11/17/2025 13:08:45

bristol-myers-faces-another-trial-disappointment-as-heart-drug-milvexian-fails-to-show-efficacy
Bristol Myers Faces Another Trial Disappoi...
11/14/2025 16:17:52

Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and ...

a-look-into-johnson--johnson-incs-price-over-earnings
A Look Into Johnson & Johnson Inc's Price ...
11/13/2025 17:00:33

decoding-johnson--johnsons-options-activity-whats-the-big-picture
Decoding Johnson & Johnson's Options Activ...
11/13/2025 16:01:52

these-20-stocks-now-make-up-half-of-the-sp-500heres-why-thats-risky
These 20 Stocks Now Make Up Half Of The S&...
11/11/2025 15:29:21

A new report shows the S&P 500 is now more concentrated than ever, with 20 companies making up over 50% of its value, drive...

fda-clears-johnson--johnsons-darzalex-faspro-enabling-early-intervention-in-myeloma-progression
FDA Clears Johnson & Johnson's Darzalex Fa...
11/07/2025 17:57:40

The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on...

fda-fast-tracks-6-more-drugs---obesity-and-cancer-drugs-included
FDA Fast-Tracks 6 More Drugs - Obesity And...
11/07/2025 14:54:21

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower prescr...

Core News & Articles
Halozyme Therapeutics Announces Johnson & ...
11/07/2025 13:31:58

Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme) today announced that Johnson & Johnson received U.S. Food and Drug Adm...

Core News & Articles
'Attor­ney Gen­er­al Ken Pax­ton Fights To...
11/06/2025 20:29:13

https://www.texasattorneygeneral.gov/news/releases/attorney-general-ken-paxton-fights-stop-manufacturer-tylenol-fraudulently-pa...

fda-approves-daratumumab-and-hyaluronidase-fihj-for-high-risk-smoldering-multiple-myeloma
FDA Approves Daratumumab And Hyaluronidase...
11/06/2025 19:52:44

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smolde...

johnson--johnson-announces-fda-approval-of-caplyta-as-adjunctive-therapy-with-antidepressants-to-treat-major-depressive-disorder-in-adults
Johnson & Johnson Announces FDA Approval O...
11/06/2025 12:37:31

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved CAPLYTA® (lumateper...

options-corner-kimberly-clarks-implosion-offers-an-unusual-informational-arbitrage-opportunity
Options Corner: Kimberly-Clark's Implosion...
11/03/2025 20:56:05

Although Kimberly-Clark suffered a huge blow after announcing its Kenvue buyout, KMB stock is flashing a quantitative contraria...

gold-edges-higher-ism-manufacturing-pmi-falls-in-october
Gold Edges Higher; ISM Manufacturing PMI F...
11/03/2025 19:23:45

alvotech-shares-plunge-33-after-fda-flags-issues
Alvotech Shares Plunge 33% After FDA Flags...
11/03/2025 18:17:22

Alvotech shares decline after the FDA issues a complete response letter for its Simponi biosimilar, leading to a lower 2025 rev...

Core News & Articles
Buffett Sells Stocks – Here Is What Pruden...
11/03/2025 16:13:32

Buffett Sells Stocks

kimberly-clark-stock-plunges-over-16-kenvue-surges-20-in-monday-pre-market-whats-going-on
Kimberly-Clark Stock Plunges Over 16%, Ken...
11/03/2025 12:16:56

Shares of Kimberly-Clark Corporation (NASDAQ: KMB) plunged 16.49% during the pre-market trading session on Monday, after it ann...

johnson--johnson-submits-application-to-us-fda-for-stelara-in-the-treatment-of-pediatric-ulcerative-colitis
Johnson & Johnson Submits Application To U...
10/31/2025 20:08:04

https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-application-to-u-s-fda-for-stelara-ustekinumab-in-the-t...

eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain
Eli Lilly Extends Lead In $150B Obesity Dr...
10/30/2025 20:04:44

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

johnson--johnson-plans-to-initiate-first-head-to-head-study-comparing-fcrn-blockers-for-patients-with-generalized-myasthenia-gravis
Johnson & Johnson Plans To Initiate First ...
10/29/2025 12:07:04

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION